Scholar Rock Holding Corporation ( SRRK) Stock. Should you Buy or Sell? $ 9.18
-0.20 (-2.23 %)
Scholar Rock Holding Corporation Analysis
Updated on 10-09-2022| Symbol | SRRK |
| Price | $9.18 |
| Beta | 0.629 |
| Volume Avg. | $1.27 M |
| Market Cap | $474.06 M |
| 52 Week Range | $4.325 - $42.54 |
Scholar Rock Holding Corporation opened the day at $9.18 which is -2.23 % on yesterday's close. Scholar Rock Holding Corporation has a 52 week high of $42.54 and 52 week low of $4.325, which is a difference of $38.215. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $474.06 M and total net profit is $18816000 which means the company is trading at 25.19 times profit to market capitalization. Theoretically, if you were to buy Scholar Rock Holding Corporation for $474.06 M, it would take 15 years to get your money back. Scholar Rock Holding Corporation are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Scholar Rock Holding Corporation Stock Forecast - Is Scholar Rock Holding Corporation a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -4.271 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -2.314 |
Valuing Scholar Rock Holding Corporation
| Price Book Value Ratio | 1.160 | Price To Book Ratio | 1.160 |
| Price To Sales Ratio | 9.884 | Price Earnings Ratio | -4.271 |
How liquid is Scholar Rock Holding Corporation
| Current Ratio | 9.689 |
| Quick Ratio | 9.230 |
Debt
| Debt Ratio | 0.223 | Debt Equity Ratio | 0.287 |
| Long Term Debt To Capitalization | 0.142 | Total Debt To Capitalization | 0.183 |
Latest news about Scholar Rock Holding Corporation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.
The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
A venture capital group significantly increased its stake in the company.
The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months.
About Scholar Rock Holding Corporation
Description :
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
